Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its ...

ChatGPT's new agent mode combines deep research, web action, and tool use to handle tasks from start to finish.

The Executive Director of the nonprofit working with residents in the old 15th Ward in Syracuse is resigning.

The New York Knicks are facing a critical offseason as they look to capitalize off of the team's Eastern Conference Finals run. Big changes have already been ma ...

A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.

An icon of two engineers reviewing a blueprint. The icon includes editable strokes or outlines using the EPS vector file.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

After signaling its intent to make "bolt-on acquisitions," Sanofi has taken a major plunge, buying out Blueprint Medicines for $9.5 billion.

Cambridge-based Blueprint Medicines brings a pipeline of experimental immunology treatments and one medicine already on sale for a rare condition known as systemic mastocytosis.

Sanofi agreed to buy Blueprint Medicines, a U.S. pharmaceutical company that specializes in rare immunological diseases, for up to $9.5 billion in a deal that seeks to strengthen the French ...